Index

age and DALYs 250, 251–2, 255–6
and QALYs 253–5, 261–2, 267–8, 330
and valuation of time 308–9
AIDS see HIV
alcohol and driving see drinking and
driving, external costs
alcohol treatment programs
benefits and effects, measurement of
160–62
as example of conjoint analysis (CA) 298–9
as example of revealed preference approach 152–3
arthritis elimination study (WTP) 338–9
Ashton, T. 48–51
asymmetric information, use of agents 222
average costs
and marginal costs 60–61, 73–4, 83
per diem method 63
and perfect competition theory 66–7
relationship to charges 69–70
Ballard, C.L. 120–21
Bayoumi, A.M. 240–42
Bleichrodt, H. 234–8
Bombardier 233
Boyle, M.H. 26, 204–6
Brent, R.J.
alcohol treatment programs study
152–3, 160–62
case management programs study
132–4, 335–8
community psychiatric care study
130–31
and discount rate, for effects 168
and federal valuation of inpatient
psychiatric care 158–60
and numbers effect/third social
objective 333–4
physician charges study 80–81
psychiatric hospitals study 127–9
social discount rates, country
estimates 180–84
and social value estimates 79
state MCF estimates 121–2, 123–4
and time as numeraire 280, 290–92
and valuation of benefits/effects 150–51, 326
Brown, G.C. 238–40
Browning, E.K. 135
Cairns, J.A. 188
cardioverter defibrillator study (CEA) 186–8
Cartwright, W.S. 312–15
case management programs study,
psychiatric care 131–4, 335–8
category rating scale (RS) 228–9, 243–4
case studies 232–8, 258–9
CBA see cost-benefit analysis (CBA)
CEA see cost-effectiveness analysis (CEA)
Chang, R.W. 213–15
charges, and costs 69–71, 84–5
costs-to-charging ratios (RCC) 70–71, 74–6
Churchill, D.N. 222, 224–5
Clark, R.E. 132
CM see cost-minimization (CM)
community psychiatric care and
marginal cost of public funds (MCF) study 129–31
confidence intervals 188–9, 190
explanation of 175
conjoint analysis (CA) 298–9
case studies 318–20
Conley, B.C. 278–9
consultations, charges relating to 81
consumer satisfaction, and taxation 118
consumer sovereignty 222–3
assumption of 13, 100, 103, 350
and occupational risk 288–9
violating 296–7, 309–15
and willingness to pay (WTP) 296–7, 309–15
consumer surplus 74–5
consumption benefits, valuation of 285–6
contingent valuation (CV) 298
case studies 272, 300, 315–17, 320, 338–9
Cook, J. 15–17
‘corner solutions’ 97
cost-benefit analysis (CBA) 6–8, 271, 293–4
basics of 11–14
benefits, components of 271–2
CM as 43–5
converting CEA into, methods 149–53, 155–62
converting CUA into, methods 279–83
efficiency measurements in 13–14
and external effects 325–6
human capital approach 273–9, 284–7, 291, 292
intangibles, measurement of 272–3, 285–6
justification for 11–12
and marginal cost of public funds (MCF) 112–16
optimal output level, establishing 41–3
social perspective in 12–13
strengths of 206, 351–2
time as numeraire 280, 290–92
utility values, whose to use 222–3
vs. CUA 202–4, 205–6
see also equity, and cost-benefit analysis (CBA); revealed preference approach; willingness to pay (WTP)
cost curves
and economic theory 33–9
long run 32, 36–9
short run 32, 34–6
U-shaped 66
cost-effectiveness analysis (CEA) 8–9, 141, 163–4, 189–90, 349–50
basic model 143–6
‘benchmark ratios’, role of 187
and CM 45–6, 48–50
conversion to CBA, methods 149–53, 155–62
‘cost-effective’, uses of term 162–3
cost-effectiveness ratios 146–9, 176–8, 187
costs, which to include 141–2
cut-off ratio 149–51, 155–8
discounting in 165, 166–73, 178–84, 190
effects, which to include 143
limitations of 141, 194
marginal cost of public funds (MCF) valuation method 150–51, 158–60
Panel on Cost-Effectiveness in Health and Medicine, recommendations 196–8, 221
preferred alternative, stages in finding 185–6
and sampling error 176–8, 184–6
and sampling variation 166
vs. CUA 193–4
cost-minimization (CM) 10, 349
case studies 35–6, 37–9, 51–6, 89, 94–8, 103–5
as a CBA 43–5
and CEA 45–6, 48–50
and economic theory 33–41
identical output condition 48–9, 58–9
importance of 58
cost-utility analysis (CUA) 9–10, 216–18, 350
basic principles 196–202
case studies 15–17, 26, 204–16
conversion to CBA, methods 279–83
cost-utility league tables/program comparisons 194–6, 206–10, 214–15, 216, 217
and priority setting 199–202
vs. CBA 202–4, 205–6
vs. CEA 193–4
see also equity, and cost-utility
analysis (CUA); QALYs (quality adjusted life years); utilities
measurement, cost-utility analysis (CUA)
costs
allocation methods  61–3
and competitive markets  64–7
definition of  31–2, 51–2
and economic theory  33–41
and non-competitive markets  67–9
costs-to-charge ratios (RCC)  70–71
comparison with relative value units (RVU)  74–6
CUA see cost-utility analysis (CUA)
Cullis, J.G.  306–8
Culyer, A.J.  67–8
DALYs (disability adjusted life years)  249
and age  250, 251–2, 255–6
and equity  249–50, 267
and global burden of disease  252–3, 264–6
HIV impact study  264–6
measurement of  250–52
sleeping sickness treatment study  262–4
decision-making, individuals, myopia in  166–7
deep-vein thrombosis study (CEA)  154–5
defibrillator study (CEA)  186–8
demand curve, theoretical derivation of  64–5
diagnostic related group (DRG) categories, costing and evaluating  74–6
Dickey, B.  130
direct costs/benefits, definition of  6
disability states classifications  226–7, 234, 251
disabled persons, valuation of quality of life improvements  218, 221
discount rates  189
in choice of industry of employment  178–80
and economic theory  166–8
effects vs. costs  171–2, 190
individual, survey and statistical analysis  188–9
recommended  172–3
social, country estimates  180–84
vaccination studies  106–7
discounting  33, 58
of benefits, in CEA  168–71
in CEA  165, 166–73, 178–84, 190
discount factors  39–41
internal rate of return  107
and lifetime disease costing  53–6
need for  165
present value  39–41
disease, measuring global burden of  252–3, 264–6
disease control/prevention  94–8
schistomiasis control study (CM)  94–8, 103–5
sleeping sickness treatment/DALYs study  262–4
syphilis prevention study (CBA)  284–6
see also HIV; vaccination programs
distribution weights (CBA)  328–32, 348–9
case studies  335–9
Dolan, P.  257–8, 325–6, 333
Donaldson, C.  315–17
Doubilet, P.  162–3
Dranove, D.  61
drinking and driving, external costs  89–91
and taxation  98–100
drug users treatment studies (WTP)  272, 300, 312–15, 331
Drummond, M.F.  5, 142, 172–3, 193–4, 206–10, 221
economic efficiency, definition of  301
economies of scale  39, 72–4
and overhead costs  61
and program evaluation problems  95–7
economies of scope  63, 72–4
Eddy, D.M.  198–9, 210–13, 215, 257, 335
effect, definition of  64, 143
elasticity see price elasticity of demand
employment, choice of occupation/risks study  178–80, 287–90
Epstein, J.F.  313
equity, and cost-benefit analysis (CBA)  323–8, 348–9
  case studies 335–47
distribution weights 328–32, 335–9, 348–9
  numbers effect 332–5, 340–43, 348–9
  and weighted cost-benefit criterion 327–8, 343–7, 349
equity, and cost-utility analysis (CUA) 246–7
  and age 250, 251–2, 253–6, 261–2, 267–8
  case studies 259–66
  DALYs 249–53, 255–6, 262–6, 267
  person trade-off (PTO) 256–9, 260–62, 266, 268, 324–5, 332–3
  QALYs 247–8, 253–5, 260–62, 266–8, 323–5
estrogen use study 225
evaluation
  components of 5–6
  definition of 4–5
  need for 3–4
  types of 6–10
  uncertainty in, methods of handling 189
excise taxes 117–18
external costs 86–9, 109–10
  case studies 98–107, 325–6, 331
dynamic evaluations 94–8
  and markets 89–94
types of 112
  see also marginal cost of public funds (MCF)
‘fair innings’ argument, QALY weights 255
financial evaluations, weaknesses of 74–5
Fingarette, H. 160
Finkler, S.A. 69, 83, 84
fixed costs 32, 34–6
  difficulty in defining 51–2
Forester, T.H. 291
French, M.T. 227, 283
Fryback, D.G. 281
gallstone treatment study (CUA) 15–17
Garbacz, C. 320
Garber, A.M. 149–50, 151, 155–8, 196
Gardiner, J. 186–8
Gatsonis, C. 25
gender weights, DALYs 249–50
Gerard, K. 216
Gertler, P.J. 328, 329, 343–7
Getzen, T.E. 25
Gold, M.R. 142, 173, 196
Grannemann, T.W. 72–4
Gregor, D.H. 23–4
Grob, G.N. 129–30
Gwatkin, D.R. 253
Hadley, J. 77–9
Hadorn, D.C. 201
Hannum, R.J. 92, 100–103, 106–7
Harper, D.R. 46–8
Harris, J. 255
health states
  index/matrix 226–7, 234
  rankings/utilities measurement
    methods study 234–8
healthy life years (HeaLYs) 264–6
healthy-years equivalent (HYE) 231
Hellinger, F.J. 55, 56
hepatitis B utility value study 227, 283
hip arthroplasty study (CUA) 213–16
Hirth, R.A. 281–2
HIV
  global burden/DALYs study 264–6
  lifetime cost study (CM) 53–6
  utility values study 240–42
Hochman, H.M. 336
Horngren, C.T. 61, 62
hospital costs 84
  and charges 69–71
  estimating 72–4
hotel costs 63
Hsiao, W.C. 76–9
Hull, R. 63, 154–5
human capital (HK) approach 14, 27, 272, 293, 350–51
  benefits, measures of 273–4
  case studies 284–7
  Conley model 278–9
  life, valuation of 291, 292
  Linneerooth model 276–8
  and mental health 275, 286–7
  QALY, valuation of 282
Index

and willingness to pay (WTP) 275–9, 294
Hurley, S. 54–6
Hyder, A.A. 264–6
hypertension
prescription/over-the-counter medicine study (WTP) 310–12
treatment sites study (CEA) 17–19, 146–9, 165–6
immunization programs see vaccination programs
implantable cardioverter defibrillator (ICD) study (CEA) 186–8
in vitro fertilization study (WTP) 318–20
income
distribution weights (CBA) 328–32, 335–9, 348–9
and incidence of communicable diseases 253
and price elasticity of demand 328–9
and risk trade-off 275–9, 287–90
and tax-transfer system 327
user fees/benefit losses study 343–7
utility of 149–50, 155–8, 302–3, 330–32
and willingness to pay (WTP) 317–20, 338–9
indirect benefits/costs, definition of 6
indirect costs, importance of inclusion 15–17
information
asymmetric, use of agents 222
and consumer sovereignty 100, 103, 288–9, 297
inputs, optimal mix, and CM 36–9
insurance, effect on relative charges 78–9
intangibles, measurement of 272–3, 285–6
interest rates, market, as discount rate 166–7
intergenerational equity 167–8, 169
internal rate of return, definition of 107
interval estimates 166
Japanese encephalitis vaccination study (CBA), sensitivity analysis 108–9
Jerrell, J.M. 132
joint/overhead costs 61–3
Kaplan, R.M. 193, 196, 200, 201, 218, 222, 234
Keeler, E.B. 170–71, 172
kidney treatment, utility values studies 220, 221, 222, 224–5
Kind, P. 207, 226–7, 234, 257
Klarman, H.E. 193, 284–6
Klevit, H.D. 200
knee arthroplasty study (CM) 35–6, 37–9, 51–3
labor supply, and taxation 125–6
law of diminishing marginal utility 64–5
law of diminishing returns 34–6, 37
length of stay (LOS) 51–3
costs related to 63
life expectancy
and DALY weights 249–50
and QALY weights 254–5, 330–31
life expectancy discount rate (LEDR) 168
lifetime consumption expenditure 106
lifetime disease costing 53–6
Lightwood, J.M. 40–41
Lindsay, C.M. 306
Linnerooth, J. 276–9
literature, use as utility values measurement source 226–7
Llewellyn-Thomas, H. 233
Logan, A.G. 18–19, 146–9, 165–6
long run cost curves 32, 36–9
marginal benefits/costs 41–3, 44–6
importance of 58
and monopolies 68–9
and perfect competition theory 64–7
time factors 94–7
see also marginal costs
marginal cost of public funds (MCF) 112–14, 136–7
case studies 122, 124–34, 135, 158–60, 335
and economic theory 117–20
estimates of 120–22, 123–4

Robert J. Brent - 9781843766988
Downloaded from Elgar Online at 12/14/2018 03:26:56PM via free access
marginal cost of public funds (MCF) (continued)

- health care evaluations, special role in 114–16
- and valuation of ‘effects’ 150–51, 158

marginal costs

- and average costs 60–61, 73–4, 83
- importance of 52–3
- and overhead costs 61

see also marginal benefits/costs

marginal utility, law of diminishing 64–5

markets

- competitive, and costs 64–7
- and external costs 89–94
- and measurement of ‘intangibles’ 272–3

non-competitive, and costs 67–9

Martin, S. 297, 304
Maynard, A. 206
Medicaid 130, 199–200, 217
Medicare, charge system 76–9
Mehrez, A. 231
Meltzer, H.Y. 56–7

meningitis vaccination valuation study (CM) 89

mental health

- mental hospital patients, earnings as valuation tool 275
- programs study (CBA) 286–7
- schizophrenia treatment studies 56–7, 184–6

see also psychiatric care, and marginal cost of public funds (MCF)

miscarriage management study (WTP) 318, 319

Mishan, E.J. 274
monopolies 67–9
Moore, M.J. 178–80, 287–90
Murray, C.J.L. 249–50, 251, 256
Musgrove, P. 89

National Health Service (NHS)

- nursing home/hospital care study (WTP) 315–17
- waiting lists/times 303–9

National Traumatic Occupational Fatality (NTOF) project 289–90

need

- as alternative to demand, for evaluations 312–15
- as defined by medical experts 312, 313
- definition of 256

neo-natal intensive care study (CUA) 26, 204–6
Neuhauer, D. 23–5
Nord, E. 232–4, 256, 257, 324, 328, 332–3, 340–43

numbers effect, and equity 332–5, 340–43, 348–9

nursing home/hospital care study (WTP) 315–17

O’Brien, B.J. 176–8

occupation choice/risks study 178–80, 287–90
Olsen, J.A. 260, 261, 266
opportunity cost 31–2
- and QALY league tables 216
- surgical ward study 46–8
- of time 50, 303–5, 308–9

ordinal scale, explanation of 237

outcomes, importance of precise estimates 25
output, definition of 64
over-the-counter/prescription drugs study (WTP) 309–12
overhead/joint costs 61–3

Panel on Cost-Effectiveness in Health and Medicine, recommendations 196–8, 221
Pareto improvements 301, 334
Patrick, D.L. 256
Pauly, M.B. 202–4
Peabody 250, 252
per diem method, average costs 63

‘person-service units’ (PSUs) 211–13

person trade-off (PTO) 256–9, 268, 324–5, 332–3

case studies 260–62, 266, 340–43

personal judgment, by analysts 225
Phelps, C.E. 98–100, 149–50, 151, 155–8, 196
Physician services
estimating resource cost of 76–9
social value of 79–81

Pigou, A.C. 166
poliomyelitis vaccination study (CBA) 105–7

Politi, C. 251–2, 262–4
prescription/over-the-counter drugs study (WTP) 309–12
present value 39–41
price elasticity of demand 80
and excess burden of taxation/marginal cost of public funds (MCF) 119–20
and income 328–9
price mechanism
competitive markets 64–7
non-competitive markets 68–9
private goods, definition of 299
privatization study, psychiatric hospitals 127–9
production function 34, 36, 37, 38
productivity
and discount rate 172
growth, and indirect cost estimates 107

Propper, C. 297, 305, 308–9
psychiatric care, and marginal cost of public funds (MCF)
case management programs study 131–4, 335–8
community care study 129–31
inpatient care, federal valuation 158–60
privatization of psychiatric hospitals, study 127–9
see also mental health
public funds, cost of see marginal cost of public funds (MCF)
public goods 95
and willingness to pay (WTP) 272, 299–300

QALYs (quality adjusted life years) 9, 193, 350
and age 253–5, 261–2, 267–8, 330
benefits, deriving from price of 283
calculation of 198–9
price of, deriving from measure of benefits 281–2, 294

using for benefits and costs 280
see also cost-utility analysis (CUA); equity, and cost-utility analysis (CUA); utilities measurement, cost-utility analysis (CUA)
Quality of Well-Being (QWB) Scale 198–9, 200, 242–3

Read, J.L. 233
relative value units (RVU)
comparison with costs-to-charge ratios (RCC) 74–6
and hospital department costs 70–71
research expenditure, evaluation of 105–6, 107
resource allocation, possible methods 11
resource based relative value (RBRV) 76–9
returns to scale 39, 73, 83–4
see also economies of scale
revealed preference approach 152–3, 160–62, 164, 297
choice of occupation/risks study 178–80, 287–90

Revicki, D.A. 56–7
Rice, D.P. 131
Richardson, J. 233
Ried, W. 231
risk
and discount rates 178–80
and income trade-off 275–9, 287–90
Rosser, R. 207, 226–7, 234, 257
Russell, L.B. 196
Ryan, M. 318–20

Sackette, D.L. 220, 221
sample selection bias 50–51, 56
sampling error
and cost-effectiveness ratios 176–8, 184–6
and statistical theory 173–6
Schimmel, V.E. 74–6
schistomiasis control study (CM) 94–8, 103–5
schizophrenia treatment studies 56–7, 184–6
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>senior companion program (SCP) study</td>
<td>320</td>
</tr>
<tr>
<td>sensitivity analysis</td>
<td>108–9</td>
</tr>
<tr>
<td>recommended rates to be used in</td>
<td>172–3</td>
</tr>
<tr>
<td>service departments, cost allocation</td>
<td>61–3</td>
</tr>
<tr>
<td>short run cost curves</td>
<td>32, 34–6</td>
</tr>
<tr>
<td>Shwartz, M.</td>
<td>70–71</td>
</tr>
<tr>
<td>side-effects</td>
<td></td>
</tr>
<tr>
<td>hypertension treatment sites study</td>
<td>17–19</td>
</tr>
<tr>
<td>valuation of</td>
<td>225, 309</td>
</tr>
<tr>
<td>Siegel</td>
<td>178, 184–6, 187, 196</td>
</tr>
<tr>
<td>Siraprapasiri, T.</td>
<td>108–9</td>
</tr>
<tr>
<td>sixth stool guaiac protocol</td>
<td>4, 23–5</td>
</tr>
<tr>
<td>sleeping sickness treatment/DALYs study</td>
<td>262–4</td>
</tr>
<tr>
<td>smear tests (cervical cancer), costs and effects</td>
<td>163</td>
</tr>
<tr>
<td>smoking cessation study</td>
<td>40–41</td>
</tr>
<tr>
<td>social costs</td>
<td>87</td>
</tr>
<tr>
<td>childhood vaccination programs study</td>
<td>100–103</td>
</tr>
<tr>
<td>and taxation</td>
<td>98–100</td>
</tr>
<tr>
<td>see also marginal cost of public funds (MCF)</td>
<td></td>
</tr>
<tr>
<td>social security benefits and marginal cost of public funds (MCF) study</td>
<td>122, 124–7</td>
</tr>
<tr>
<td>social time preference rate (STPR)</td>
<td>167–8</td>
</tr>
<tr>
<td>Spearman rank correlation coefficient, explanation of</td>
<td>237</td>
</tr>
<tr>
<td>speed limit study (CBA)</td>
<td>290–92</td>
</tr>
<tr>
<td>Squire, L.</td>
<td>168, 331–2, 335</td>
</tr>
<tr>
<td>standard deviation, explanation of</td>
<td>173–4</td>
</tr>
<tr>
<td>standard error, explanation of</td>
<td>175</td>
</tr>
<tr>
<td>standard gamble (SG)</td>
<td>229–30, 231, 243–4</td>
</tr>
<tr>
<td>case studies</td>
<td>213–15, 232–42</td>
</tr>
<tr>
<td>Stason, W.B.</td>
<td>225</td>
</tr>
<tr>
<td>statistical significance</td>
<td>176, 188–9, 190</td>
</tr>
<tr>
<td>step-down allocation method</td>
<td>62–3</td>
</tr>
<tr>
<td>Stern, S.H.</td>
<td>35–6, 37–9, 51–3</td>
</tr>
<tr>
<td>stigma, valuation of</td>
<td>286</td>
</tr>
<tr>
<td>stool study see sixth stool guaiac protocol</td>
<td></td>
</tr>
<tr>
<td>sunk costs</td>
<td>60–1</td>
</tr>
<tr>
<td>supply curve, theoretical derivation of</td>
<td>65–6</td>
</tr>
<tr>
<td>surgical ward study (opportunity cost)</td>
<td>46–8</td>
</tr>
<tr>
<td>switching values</td>
<td>88–9, 99–100, 108–9</td>
</tr>
<tr>
<td>syphilis prevention study (CBA)</td>
<td>284–6</td>
</tr>
<tr>
<td>taxation</td>
<td></td>
</tr>
<tr>
<td>and drinking and driving</td>
<td>98–100</td>
</tr>
<tr>
<td>excess burden of</td>
<td>117–20, 135, 136</td>
</tr>
<tr>
<td>and income redistribution</td>
<td>327</td>
</tr>
<tr>
<td>and labor supply</td>
<td>125–6</td>
</tr>
<tr>
<td>optimal commodity taxes</td>
<td>91, 98–100</td>
</tr>
<tr>
<td>rates of, importance</td>
<td>135</td>
</tr>
<tr>
<td>see also marginal cost of public funds (MCF)</td>
<td></td>
</tr>
<tr>
<td>Temin, P.</td>
<td>309–12</td>
</tr>
<tr>
<td>Thaler, R.</td>
<td>312</td>
</tr>
<tr>
<td>Thompson, M.S.</td>
<td>338–9</td>
</tr>
<tr>
<td>time</td>
<td></td>
</tr>
<tr>
<td>opportunity cost of</td>
<td>50, 303–5, 308–9</td>
</tr>
<tr>
<td>rationing by, and willingness to pay (WTP)</td>
<td>303–9, 322</td>
</tr>
<tr>
<td>treatment delay, and loss of benefits</td>
<td>306–9</td>
</tr>
<tr>
<td>as valuation unit</td>
<td>280, 290–92, 297</td>
</tr>
<tr>
<td>time trade-off model (TTO)</td>
<td>230–31, 243–4</td>
</tr>
<tr>
<td>case studies</td>
<td>220, 224, 232–42</td>
</tr>
<tr>
<td>topical hydrocortisone</td>
<td></td>
</tr>
<tr>
<td>prescription/over-the-counter study (WTP)</td>
<td>309–10, 311</td>
</tr>
<tr>
<td>Torrance, G.W.</td>
<td>194–5, 204, 220, 221, 223, 225, 230, 233</td>
</tr>
<tr>
<td>total hip arthroplasty (THA) study (CUA)</td>
<td>213–16</td>
</tr>
<tr>
<td>transfer payments</td>
<td>115–16, 136</td>
</tr>
<tr>
<td>case management programs</td>
<td>132–4, 332–8</td>
</tr>
<tr>
<td>and distribution weights</td>
<td>335–8</td>
</tr>
<tr>
<td>in privatization</td>
<td>127</td>
</tr>
<tr>
<td>social security benefits</td>
<td>122, 124–7</td>
</tr>
<tr>
<td>trypanosomiasis (sleeping sickness) treatment/DALYs study</td>
<td>262–4</td>
</tr>
<tr>
<td>Tsuchiya, A.</td>
<td>254, 256</td>
</tr>
<tr>
<td>Ulbe, P.A.</td>
<td>258–9, 333</td>
</tr>
<tr>
<td>ulcer treatment study (CEA/CM)</td>
<td>48–51</td>
</tr>
</tbody>
</table>
user fees (Peru) study 343–7
utilities measurement, cost-utility analysis (CUA) 219, 243–4
case studies 220, 222, 224–5, 232–42
category rating scale (RS) 228–9
duration, as a factor 220, 242–3, 244
measurement stages 219–20
methods 228–31, 232–8, 243–4
sources, for establishment of values 225–8
standard gamble (SG) 229–30, 231
statistical accuracy 223–5
time trade-off model (TTO) 230–31
utility values, whose to use 221–3
see also equity, and cost-utility analysis (CUA); QALYs (quality adjusted life years)
utility of income 149–50, 155–8, 302–3, 330–32
law of diminishing marginal 64–5
vaccination programs
childhood, social costs/vaccination rates study 100–103
external benefits 91–4
Japanese encephalitis study (CBA), sensitivity analysis 108–9
meningitis, valuation study (CM) 89
poliomyelitis study (CBA) 105–7
Vaillant, G.E. 160
Van Hout, B.A. 170, 171
variable costs 32, 34–6
vision acuity utility values study 238–40
Von Neumann, J. 230
Wagstaff, A. 246, 248
waiting lists/times, rationing by 303–9
walking ability study (PTO) 340–43
Weimer, C. 94–8, 103–5
Weinstein, M.C. 142, 143–6, 169–70, 171–2, 196, 221, 225
Weintraub, W.S. 82
Weisbrod, B.A. 105–7, 275, 286–7
‘well year’, definition of 193
Wildasin, D.E. 122, 124–7, 135
Williams, A. 255, 323
willingness to accept (WTA) 301–3, 320
willingness to pay (WTP) 14, 321–2
advantages of 351
case studies 272, 300, 309–20, 331, 338–9
and compensation tests 301, 315–17, 334
as comprehensive measure of benefits 272
Conley model 278–9
and consumer sovereignty 296–7, 309–15
and demand curve 64–5
direct estimates 309–10, 311, 312–15, 322
and economic efficiency 301
and human capital approach 275–9, 294
and income 317–20, 338–9
indirect estimates 310–12, 322
life, valuation of 274, 275–9, 287–90
Linnerooth model 276–8
and psychiatric patients 275
and public goods 272, 299–300
QALY, valuation of 282
and rationing by time 303–9, 322
valuation methods 297–9
see also revealed preference approach
World Bank, global disease study 252–3
Wyatt, R.J. 4
Zarkin, G.A. 272, 300, 325, 331